I'll start with some news of the day: The FDA approved its first Alzheimer's drug  to delay dementia. Aducanumab by Biogen, to be sold as Aduhelm. However, it comes with an annual cost of $56,000, plus an additional major diagnostic test expense.   Of course Biogen stock value shot up.   More than 6 million Americans have Alzheimer's, with more than a doubling expected by 2050. All this after somewhat inconclusive tests about the effectiveness of this drug. What this means is that the FDA has effectively concluded that targeting that sticky brain compound, beta-amyloid, is a worthy solution. But the cost and lack of convincing data will mean that medical plans and doctors will show huge reluctance to proceed. My reading of the politics of the Senate and Biden Administration is that the White House has pretty much given up passing liberal and filibuster-killing legislation because of Senator Joe Manchin , who, while a Democrat, barely got elected the last time in West Virgi